Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
MediGene AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'MediGene AG - Product Pipeline Review - 2014', provides an overview of the MediGene AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of MediGene AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of MediGene AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of MediGene AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the MediGene AG's pipeline products Reasons to buy - Evaluate MediGene AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of MediGene AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the MediGene AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of MediGene AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of MediGene AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of MediGene AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 MediGene AG Snapshot 5 MediGene AG Overview 5 Key Information 5 Key Facts 5 MediGene AG - Research and Development Overview 6 Key Therapeutic Areas 6 MediGene AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 MediGene AG - Pipeline Products Glance 11 MediGene AG - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 MediGene AG - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 MediGene AG - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 MediGene AG - Drug Profiles 15 paclitaxel lipsomal 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 sinecatechins 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Dendritic Cell Vaccine for Prostate Cancer 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 RhuDex 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Dendritic Cell Vaccine For Acute Myeloid Leukemia (AML) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 AAVLP Program 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Adoptive T Cell Therapy for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 MediGene AG - Pipeline Analysis 25 MediGene AG - Pipeline Products by Target 25 MediGene AG - Pipeline Products by Route of Administration 26 MediGene AG - Pipeline Products by Molecule Type 27 MediGene AG - Pipeline Products by Mechanism of Action 28 MediGene AG - Recent Pipeline Updates 29 MediGene AG - Dormant Projects 33 MediGene AG - Discontinued Pipeline Products 34 Discontinued Pipeline Product Profiles 34 etomoxir 34 G-207 34 L1 Monoclonal Antibody 34 MediGene AG - Company Statement 35 MediGene AG - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables MediGene AG, Key Information 5 MediGene AG, Key Facts 5 MediGene AG - Pipeline by Indication, 2014 8 MediGene AG - Pipeline by Stage of Development, 2014 9 MediGene AG - Monotherapy Products in Pipeline, 2014 10 MediGene AG - Phase III, 2014 11 MediGene AG - Phase II, 2014 12 MediGene AG - Phase I, 2014 13 MediGene AG - Preclinical, 2014 14 MediGene AG - Pipeline by Target, 2014 25 MediGene AG - Pipeline by Route of Administration, 2014 26 MediGene AG - Pipeline by Molecule Type, 2014 27 MediGene AG - Pipeline Products by Mechanism of Action, 2014 28 MediGene AG - Recent Pipeline Updates, 2014 29 MediGene AG - Dormant Developmental Projects,2014 33 MediGene AG - Discontinued Pipeline Products, 2014 34 MediGene AG, Subsidiaries 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.